To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants

Sponsor
Eli Lilly and Company
Study ID
NCT06808802
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
21 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Retatrutide — DRUG
    Administered subcutaneously (SC)
  • Metoprolol — DRUG
    Administered orally

Study Details

The purpose of this study J1I-MC-GZQE is to measure the effect of retatrutide on the pharmacokinetics (PK) of metoprolol in healthy participants.

Key Dates

Start date
Feb 3, 2025
Status verified
Jun 2025
Primary completion
Apr 15, 2025
Completion
Apr 15, 2025

Study Design

Enrollment
30 participants (actual)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Retatrutide
    In period 1, participants will be administered a singe oral dose of metoprolol followed by a 1-week washout before retatrutide subcutaneous (SC) injection is given in period 2, followed by a second dose of metoprolol.

Primary Outcome Measure

Pharmacokinetics (PK): Area Under Concentration From Time Zero to Infinity (AUC[0-∞]) of Metoprolol [ Time Frame: Day 1 to Day 3 ]

Related Studies